Telomir Pharmaceuticals Cash Flow Statement 2022-2024 | TELO

Fifteen years of historical annual cash flow statements for Telomir Pharmaceuticals (TELO).

Annual Data | Millions of US $ except per share data

Metric Name
Net Income/Loss
Total Depreciation And Amortization - Cash Flow
Other Non-Cash Items
Total Non-Cash Items
Change In Accounts Receivable
Change In Inventories
Change In Accounts Payable
Change In Assets/Liabilities
Total Change In Assets/Liabilities
Cash Flow From Operating Activities
Net Change In Property, Plant, And Equipment
Net Change In Intangible Assets
Net Acquisitions/Divestitures
Net Change In Short-term Investments
Net Change In Long-Term Investments
Net Change In Investments - Total
Investing Activities - Other
Cash Flow From Investing Activities
Net Long-Term Debt
Net Current Debt
Debt Issuance/Retirement Net - Total
Net Common Equity Issued/Repurchased
Net Total Equity Issued/Repurchased
Total Common And Preferred Stock Dividends Paid
Financial Activities - Other
Cash Flow From Financial Activities
Net Cash Flow
Stock-Based Compensation
Common Stock Dividends Paid
20232022
$-13.07$-0.85
$1.61$0
$7.49$0
$9.10$0
$0$0
$0$0
$0$0
$0.00$0
$0.11$0.39
$-3.86$-0.47
$0$0
$0$0
$0$0
$0$0
$0$0
$0$0
$0$0
$0$0
$3.12$0.46
$0$0
$3.12$0.46
$1.00$0
$1.00$0
$0$0
$-0.26$0.01
$3.86$0.47
$0.00$0.00
$0$0
$0$0